[go: up one dir, main page]

ATE554756T1 - Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen - Google Patents

Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen

Info

Publication number
ATE554756T1
ATE554756T1 AT02717548T AT02717548T ATE554756T1 AT E554756 T1 ATE554756 T1 AT E554756T1 AT 02717548 T AT02717548 T AT 02717548T AT 02717548 T AT02717548 T AT 02717548T AT E554756 T1 ATE554756 T1 AT E554756T1
Authority
AT
Austria
Prior art keywords
treatment
chemotherapeutics
combination
proliferative diseases
epothilone analog
Prior art date
Application number
AT02717548T
Other languages
English (en)
Inventor
Francis Lee
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE554756T1 publication Critical patent/ATE554756T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT02717548T 2001-03-14 2002-03-05 Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen ATE554756T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27580101P 2001-03-14 2001-03-14
US31639501P 2001-08-31 2001-08-31
PCT/US2002/006746 WO2002072085A1 (en) 2001-03-14 2002-03-05 Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
ATE554756T1 true ATE554756T1 (de) 2012-05-15

Family

ID=29254237

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02717548T ATE554756T1 (de) 2001-03-14 2002-03-05 Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen

Country Status (26)

Country Link
US (5) US7312237B2 (de)
EP (1) EP1383490B1 (de)
JP (1) JP2004529904A (de)
KR (1) KR20040025904A (de)
CN (1) CN1496256A (de)
AT (1) ATE554756T1 (de)
AU (1) AU2002248542B9 (de)
BG (1) BG66289B1 (de)
BR (1) BRPI0207961B8 (de)
CA (1) CA2440555A1 (de)
CZ (1) CZ305799B6 (de)
EE (1) EE05417B1 (de)
ES (1) ES2384789T3 (de)
HK (1) HK1060843A1 (de)
HR (1) HRP20030831B1 (de)
HU (1) HU230273B1 (de)
IL (2) IL157443A0 (de)
IS (1) IS2882B (de)
MX (1) MXPA03008135A (de)
NO (1) NO333972B1 (de)
PL (1) PL368973A1 (de)
RU (1) RU2321400C2 (de)
SK (1) SK11082003A3 (de)
TW (1) TWI330530B (de)
WO (1) WO2002072085A1 (de)
ZA (1) ZA200307123B (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
JP4579351B2 (ja) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
WO2002058699A1 (en) 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
WO2002066038A1 (en) 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Treatment of refractory tumors using epothilone derivatives
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
SK1102004A3 (sk) * 2001-08-31 2005-05-05 Bristol-Myers Squibb Company Liečivo na liečenie proliferačných ochorení a farmaceutická kompozícia na liečenie rakoviny
TWI341728B (en) * 2002-01-14 2011-05-11 Novartis Ag Combinations comprising epothilones and anti-metabolites
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
CA2487147A1 (en) * 2002-06-10 2003-12-18 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
AU2003243561A1 (en) * 2002-06-14 2003-12-31 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
CN102532120A (zh) * 2002-08-23 2012-07-04 索隆-基特林癌症研究协会 埃坡霉素(epothilone)，合成埃坡霉素的中间体，其类似物及其用途
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
AU2003279923A1 (en) * 2002-10-09 2004-05-04 Kosan Biosciences, Inc. Epo D + 5-FU/GEMCITABINE
GB0305928D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
EP1663214A1 (de) * 2003-09-02 2006-06-07 Novartis AG Krebsbehandlung mit epothilonen
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20050272068A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. UCH-L1 expression and cancer therapy
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
CA2559285A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005089515A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
CA2559282A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
JP2007538004A (ja) * 2004-03-18 2007-12-27 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド シヌクレイノパチーを治療する方法
US20050215604A1 (en) * 2004-03-26 2005-09-29 Kosan Biosciences, Inc. Combination therapies with epothilones and carboplatin
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
CN1988904A (zh) * 2004-07-26 2007-06-27 诺瓦提斯公司 埃坡霉素组合
PE20061058A1 (es) 2004-11-18 2006-10-13 Bristol Myers Squibb Co Composicion farmaceutica que comprende ixabepilona y proceso de preparacion
US20060134214A1 (en) * 2004-11-18 2006-06-22 Ismat Ullah Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
CA2597647A1 (en) 2005-02-11 2007-08-02 University Of Southern California Method of expressing proteins with disulfide bridges
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
WO2006105127A2 (en) 2005-03-31 2006-10-05 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
US20070190544A1 (en) * 2005-10-28 2007-08-16 Emory University Methods of screening for resistance to microtuble-targeting drugs
CA2647565A1 (en) 2006-03-31 2007-10-18 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
JP2009536153A (ja) * 2006-04-05 2009-10-08 ノバルティス アクチエンゲゼルシャフト 癌を処置するための治療剤の組合せ
EP2029156A4 (de) * 2006-05-01 2010-07-21 Univ Southern California Kombinationstherapie zur krebsbehandlung
CN101732310B (zh) * 2006-07-12 2011-07-20 湖南迪诺制药有限公司 埃博霉素b的用途
EP2962731A1 (de) * 2008-01-08 2016-01-06 Bristol-Myers Squibb Company Kombination aus ipilimumab und paclitaxel zur behandlung von krebs
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
WO2010057006A1 (en) * 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
JP5881254B2 (ja) 2010-05-18 2016-03-09 セルリアン・ファーマ・インコーポレイテッド 自己免疫疾患およびその他の疾患の治療のための組成物および方法
US8435972B2 (en) * 2010-09-02 2013-05-07 Emory University Method for the treatment of central nervous system cancers and compositions related thereto
EP2717884A1 (de) 2011-06-06 2014-04-16 Chevron Phillips Chemical Company LP Verwendung von metallocenverbindungen zur krebsbehandlung
US11478505B2 (en) 2020-01-10 2022-10-25 R-Pharm Us Operating Llc Compositions of ixabepilone
TW202326134A (zh) * 2021-12-24 2023-07-01 國立清華大學 用於破壞細胞內微管的方法及平台

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4247942A (en) * 1961-03-01 1981-01-27 Ford Aerospace & Communications Corp. Jam resistant communication system
CH513157A (de) * 1967-02-27 1971-09-30 Hoffmann La Roche Verfahren zur Herstellung von Pyrrolinverbindungen
US3831013A (en) * 1973-02-20 1974-08-20 Us Navy Correlators using shift registers
US3900721A (en) * 1974-02-14 1975-08-19 Us Navy Serial-access linear transform
US4653069A (en) * 1975-11-06 1987-03-24 General Electric Company Spread spectrum correlation receiver
US4112372A (en) * 1977-01-11 1978-09-05 Texas Instruments Incorporated Spread spectrum communication system
US4285060A (en) * 1978-02-28 1981-08-18 Harris Corporation Spread spectrum code tracking loop
US4193031A (en) * 1978-03-13 1980-03-11 Purdue Research Foundation Method of signal transmission and reception utilizing wideband signals
US4189677A (en) * 1978-03-13 1980-02-19 Purdue Research Foundation Demodulator unit for spread spectrum apparatus utilized in a cellular mobile communication system
US4222115A (en) * 1978-03-13 1980-09-09 Purdue Research Foundation Spread spectrum apparatus for cellular mobile communication systems
DE3023375C1 (de) * 1980-06-23 1987-12-03 Siemens Ag, 1000 Berlin Und 8000 Muenchen, De
US4455651A (en) * 1980-10-20 1984-06-19 Equatorial Communications Company Satellite communications system and apparatus
US4730340A (en) * 1980-10-31 1988-03-08 Harris Corp. Programmable time invariant coherent spread symbol correlator
US4392232A (en) * 1981-09-28 1983-07-05 B-Systems, Inc. Simplified transversal correlator for MSK and MSK related waveforms
US4425642A (en) * 1982-01-08 1984-01-10 Applied Spectrum Technologies, Inc. Simultaneous transmission of two information signals within a band-limited communications channel
US4479226A (en) * 1982-03-29 1984-10-23 At&T Bell Laboratories Frequency-hopped single sideband mobile radio system
US4563774A (en) * 1982-10-25 1986-01-07 At&T Bell Laboratories Address coded communication system
US4755983A (en) * 1983-03-01 1988-07-05 Hazeltine Corporation Dedicated message matched filter
US4523311A (en) * 1983-04-11 1985-06-11 At&T Bell Laboratories Simultaneous transmission of speech and data over an analog channel
US4512013A (en) * 1983-04-11 1985-04-16 At&T Bell Laboratories Simultaneous transmission of speech and data over an analog channel
US4538280A (en) * 1983-05-05 1985-08-27 E-Systems, Inc. Coherent spread spectrum pseudonoise tracking loop
FR2549663A1 (fr) * 1983-07-21 1985-01-25 Snecma Procede et dispositif pour le codage et le decodage d'une emission a large bande
GB2144310A (en) * 1983-08-01 1985-02-27 Philips Electronic Associated Multiple-access communications system
US4649549A (en) * 1983-08-30 1987-03-10 Sophisticated Signals And Circuits Apparatus for synchronizing linear PN sequences
US4641322A (en) * 1983-10-18 1987-02-03 Nec Corporation System for carrying out spread spectrum communication through an electric power line
JPS60103834A (ja) * 1983-11-11 1985-06-08 Nippo Tsushin Kogyo Kk 個人呼出通信システム
US4660164A (en) * 1983-12-05 1987-04-21 The United States Of America As Represented By The Secretary Of The Navy Multiplexed digital correlator
US4672605A (en) * 1984-03-20 1987-06-09 Applied Spectrum Technologies, Inc. Data and voice communications system
JPS60220635A (ja) * 1984-04-17 1985-11-05 Clarion Co Ltd スペクトラム拡散送受信機
DE3427058A1 (de) * 1984-07-23 1986-02-06 Standard Elektrik Lorenz Ag, 7000 Stuttgart Empfaenger fuer bandgespreizte signale
US4639914A (en) * 1984-12-06 1987-01-27 At&T Bell Laboratories Wireless PBX/LAN system with optimum combining
DE3447107A1 (de) * 1984-12-22 1986-06-26 Philips Patentverwaltung Gmbh, 2000 Hamburg Verfahren zur nachrichtenuebertragung in einem digitalen funkuebertragungssystem
GB2171576B (en) * 1985-02-04 1989-07-12 Mitel Telecom Ltd Spread spectrum leaky feeder communication system
US4675839A (en) * 1985-04-10 1987-06-23 Allied Corporation Receiver for a spread spectrum communication system having a time-multiplexed convolver
CA1259430A (en) * 1985-07-19 1989-09-12 Fumio Akashi Multipoint communication system having polling and reservation schemes
US4672658A (en) * 1985-10-16 1987-06-09 At&T Company And At&T Bell Laboratories Spread spectrum wireless PBX
US4647863A (en) * 1985-11-01 1987-03-03 The United States Of America As Represented By The Secretary Of The Army Saw transition detector for PSK signals
US4718080A (en) * 1985-12-16 1988-01-05 Serrano Arthur L Microprocessor controlled interface for cellular system
US4703474A (en) * 1986-02-28 1987-10-27 American Telephone And Telegraph Company, At&T Bell Laboratories Spread spectrum code-division-multiple-access (SS-CDMA) lightwave communication system
FR2595889B1 (fr) * 1986-03-14 1988-05-06 Havel Christophe Dispositif de controle de puissance d'emission dans une station emettrice-receptrice de radiocommunication
JPS6374330A (ja) * 1986-09-18 1988-04-04 Sony Corp 無線通信方法及びそれに用いる通信機
JPS6397033A (ja) * 1986-10-14 1988-04-27 Kenwood Corp スペクトラム拡散通信方式における同期パルス発生回路
US4901307A (en) * 1986-10-17 1990-02-13 Qualcomm, Inc. Spread spectrum multiple access communication system using satellite or terrestrial repeaters
US4759034A (en) * 1986-12-02 1988-07-19 General Research Of Electronics, Inc. Multi-step spread spectrum communication apparatus
US4775995A (en) * 1986-12-22 1988-10-04 Motorola, Inc. Adaptive splatter control
US4932037A (en) * 1987-02-11 1990-06-05 Hillier Technologies Limited Partnership Remote control system, components and methods
JP2624964B2 (ja) * 1987-06-09 1997-06-25 キヤノン株式会社 無線通信装置
US4799253A (en) * 1987-07-20 1989-01-17 Motorola, Inc. Colocated cellular radiotelephone systems
US4899364A (en) * 1987-07-31 1990-02-06 Clarion Co., Ltd. Automatic gain control system
US4850036A (en) * 1987-08-21 1989-07-18 American Telephone And Telegraph Company Radio communication system using synchronous frequency hopping transmissions
US4894842A (en) * 1987-10-15 1990-01-16 The Charles Stark Draper Laboratory, Inc. Precorrelation digital spread spectrum receiver
US4922506A (en) * 1988-01-11 1990-05-01 Sicom Corporation Compensating for distortion in a communication channel
US4805208A (en) * 1988-01-15 1989-02-14 Niravoice, Inc. Modem compression system for telephone network
US4914651A (en) * 1988-09-20 1990-04-03 Cellular Data, Inc. Cellular data system
EP0369923B1 (de) * 1988-11-15 1993-09-15 José Vidal Sans Verschlusselement zur Kontrolle von Ileokolostomie
US4930140A (en) * 1989-01-13 1990-05-29 Agilis Corporation Code division multiplex system using selectable length spreading code sequences
JPH07120968B2 (ja) * 1989-02-07 1995-12-20 クラリオン株式会社 スペクトラム拡散通信装置
JP2718978B2 (ja) * 1989-03-02 1998-02-25 株式会社トキメック データ伝送方式
US4991164A (en) * 1989-03-23 1991-02-05 Telettra-Telefonia Elettronica E Radio S.P.A. Automatic transmit power level control in radio links
US4993021A (en) * 1989-03-23 1991-02-12 Telettra-Telefonia Elettronica E Radio Spa Automatic transmit power level control in radio links
JP2769478B2 (ja) * 1989-04-10 1998-06-25 三菱電機株式会社 無線機
JP2720076B2 (ja) * 1989-07-17 1998-02-25 京セラ株式会社 直接スペクトラム拡散受信機の自動校正装置
US5016255A (en) * 1989-08-07 1991-05-14 Omnipoint Data Company, Incorporated Asymmetric spread spectrum correlator
US5022047A (en) * 1989-08-07 1991-06-04 Omnipoint Data Corporation Spread spectrum correlator
US5016256A (en) * 1989-10-17 1991-05-14 Stewart Clarence H Spread spectrum intercept apparatus and method
US5101501A (en) * 1989-11-07 1992-03-31 Qualcomm Incorporated Method and system for providing a soft handoff in communications in a cdma cellular telephone system
US5056109A (en) * 1989-11-07 1991-10-08 Qualcomm, Inc. Method and apparatus for controlling transmission power in a cdma cellular mobile telephone system
US5109390A (en) * 1989-11-07 1992-04-28 Qualcomm Incorporated Diversity receiver in a cdma cellular telephone system
US5257283A (en) * 1989-11-07 1993-10-26 Qualcomm Incorporated Spread spectrum transmitter power control method and system
US5005169A (en) * 1989-11-16 1991-04-02 Westinghouse Electric Corp. Frequency division multiplex guardband communication system for sending information over the guardbands
US5073900A (en) * 1990-03-19 1991-12-17 Mallinckrodt Albert J Integrated cellular communications system
JP2748656B2 (ja) * 1990-06-19 1998-05-13 ソニー株式会社 移動無線通信方法
US5103459B1 (en) * 1990-06-25 1999-07-06 Qualcomm Inc System and method for generating signal waveforms in a cdma cellular telephone system
US5040238A (en) * 1990-06-29 1991-08-13 Motorola, Inc. Trunking system communication resource reuse method
US5129098A (en) * 1990-09-24 1992-07-07 Novatel Communication Ltd. Radio telephone using received signal strength in controlling transmission power
US5093840A (en) * 1990-11-16 1992-03-03 Scs Mobilecom, Inc. Adaptive power control for a spread spectrum transmitter
US5299226A (en) * 1990-11-16 1994-03-29 Interdigital Technology Corporation Adaptive power control for a spread spectrum communications system and method
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5396516A (en) * 1993-02-22 1995-03-07 Qualcomm Incorporated Method and system for the dynamic modification of control paremeters in a transmitter power control system
US6441026B1 (en) 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
DE59609305D1 (de) 1995-11-17 2002-07-11 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Herstellung
US5758687A (en) * 1996-05-13 1998-06-02 Funicello; John C. Dual arm overhead air supply system
JP2001500851A (ja) 1996-08-30 2001-01-23 ノバルティス アクチエンゲゼルシャフト エポシロンの製造法および製造過程中に得られる中間生産物
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
CZ303422B6 (cs) 1996-11-18 2012-09-05 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilon C, zpusob jeho výroby a jeho použití jako cytostatik a prostredku pro ochranu rostlin
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
JP4579351B2 (ja) * 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US6867305B2 (en) * 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
DE59805110D1 (de) 1997-02-25 2002-09-12 Biotechnolog Forschung Gmbh Seitenkettenmodifizierte epothilone
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
CA2286610C (en) 1997-04-18 2007-03-13 Studiengesellschaft Kohle Mbh Selective olefin metathesis of bifunctional or polyfunctional substrates in compressed carbon dioxide as reaction medium
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6384230B1 (en) 1997-07-16 2002-05-07 Schering Aktiengesellschaft Thiazole derivatives, method for their production and use
ES2290993T3 (es) 1997-08-09 2008-02-16 Bayer Schering Pharma Aktiengesellschaft Nuevos derivados de epotilona, proceso para su produccion y su utilizacion farmaceutica.
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
CA2320182C (en) 1998-02-05 2008-11-25 Novartis Ag Compositions containing organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
EP1058679B1 (de) 1998-02-25 2005-10-19 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
WO2000000485A1 (de) 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
US6326390B1 (en) * 1998-08-25 2001-12-04 King Pharmaceuticals Reseach And Development, Inc. Use of adenosine A3 receptor antagonists to inhibit tumor growth
AU768220B2 (en) 1998-11-20 2003-12-04 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
CN1122668C (zh) 1998-12-22 2003-10-01 诺瓦提斯公司 环氧噻酮衍生物，其制备方法及其药物组合物
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
AU783992B2 (en) 1998-12-23 2006-01-12 G.D. Searle Llc Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20030191162A1 (en) 1998-12-31 2003-10-09 Sugen Inc. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
BR9916735A (pt) 1998-12-31 2001-09-25 Sugen Inc Compostos de 3-heteroarilidenil-2-indolinona para a modulação da atividade das cinases protéicas e para uso na quimioterapia do cancêr
DE19908760A1 (de) * 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
HUP0105478A3 (en) 1999-02-18 2002-08-28 Schering Ag 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
KR100685336B1 (ko) 1999-02-22 2007-02-23 게젤샤프트 퓌어 비오테크놀로기쉐 포르슝 엠베하(게베에프) Ｃ-21 변형 에포틸론
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
GB9909925D0 (en) 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
PE20010116A1 (es) 1999-04-30 2001-02-15 Schering Ag Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion
US6982265B1 (en) * 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
AU5286999A (en) 1999-07-23 2001-02-13 Glaxo Group Limited Combination of an anti-ep-cam antibody with a chemotherapeutic agent
AU1595001A (en) 1999-11-11 2001-06-06 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
EP1259234B9 (de) 1999-12-30 2007-02-14 Sugen, Inc. 3-heteroarylidenyl-2-indolinon derivate mit protein kinase modulierender activity und zur verwendung in der krebschemotherapie
US6280395B1 (en) * 2000-01-19 2001-08-28 Mpr Health Systems, Inc. System and method for determining muscle dysfunction
WO2001064650A2 (en) * 2000-03-01 2001-09-07 Sloan-Kettering Institute For Cancer Research Center Synthesis of epothilones, intermediates thereto and analogues thereof
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US6589968B2 (en) * 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
US6462017B1 (en) 2000-05-01 2002-10-08 Sciclone Pharmaceuticals, Inc. Method of reducing side effects of chemotherapy in cancer patients
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
AR033680A1 (es) 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
US6822001B2 (en) 2000-11-03 2004-11-23 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
US20020147198A1 (en) * 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US6828452B2 (en) 2001-01-18 2004-12-07 Cognis Deutschland Gmbh & Co. Kg Method for producing acyl amino acids
HUP0302567A2 (hu) 2001-01-25 2003-12-29 Bristol-Myers Squibb Co. Epotilon analógokat tartalmazó parenterális adagolási formák és eljárás az előállításukra
EE05301B1 (et) 2001-01-25 2010-06-15 Bristol-Myers Squibb Company Meetod epotilooni analooge sisaldavate ravimvormide valmistamiseks ning nende kasutamine ravimi valmistamiseks
WO2002058699A1 (en) 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
US6548531B2 (en) 2001-02-09 2003-04-15 Hoffmann-La Roche Inc. Method for cancer therapy
WO2002066038A1 (en) 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Treatment of refractory tumors using epothilone derivatives
CN1610549A (zh) 2001-02-20 2005-04-27 布里斯托尔-迈尔斯斯奎布公司 用于治疗难治肿瘤的埃坡霉素衍生物
ATE434438T1 (de) 2001-02-27 2009-07-15 Novartis Pharma Gmbh Kombination enthaltend einen inhibitor der signaltransduktion und ein epothilonderivat
WO2002074042A2 (en) 2001-03-19 2002-09-26 Novartis Ag Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
ATE344041T1 (de) 2001-05-03 2006-11-15 Hoffmann La Roche Kombination eines gelatinasehemmers und eines anti-tumor-agent, und deren verwendung
US6680306B2 (en) 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
TWI341728B (en) 2002-01-14 2011-05-11 Novartis Ag Combinations comprising epothilones and anti-metabolites

Also Published As

Publication number Publication date
ES2384789T3 (es) 2012-07-12
HU230273B1 (hu) 2015-11-30
US8569347B2 (en) 2013-10-29
US8598215B2 (en) 2013-12-03
EP1383490A1 (de) 2004-01-28
AU2002248542B2 (en) 2007-01-18
BG66289B1 (en) 2013-02-28
EE05417B1 (et) 2011-06-15
BRPI0207961A8 (pt) 2017-09-19
BRPI0207961B1 (pt) 2019-11-19
HK1060843A1 (en) 2004-08-27
US20030073677A1 (en) 2003-04-17
US20100015149A1 (en) 2010-01-21
IL157443A (en) 2011-12-29
MXPA03008135A (es) 2003-12-12
US20110033457A1 (en) 2011-02-10
AU2002248542B9 (en) 2007-04-26
IL157443A0 (en) 2004-03-28
BR0207961A (pt) 2004-04-20
RU2321400C2 (ru) 2008-04-10
TWI330530B (en) 2010-09-21
CZ20032376A3 (cs) 2004-09-15
US20040214871A1 (en) 2004-10-28
HRP20030831B1 (en) 2012-08-31
NO333972B1 (no) 2013-11-04
PL368973A1 (en) 2005-04-04
CZ305799B6 (cs) 2016-03-23
HUP0400203A2 (hu) 2004-08-30
SK11082003A3 (sk) 2004-08-03
NO20034056D0 (no) 2003-09-12
HRP20030831A2 (en) 2004-08-31
EP1383490A4 (de) 2009-03-18
ZA200307123B (en) 2005-02-23
IS6950A (is) 2003-09-12
EP1383490B1 (de) 2012-04-25
HUP0400203A3 (en) 2006-02-28
IS2882B (is) 2014-05-15
WO2002072085A1 (en) 2002-09-19
JP2004529904A (ja) 2004-09-30
US20050159461A1 (en) 2005-07-21
CA2440555A1 (en) 2002-09-19
BRPI0207961B8 (pt) 2021-05-25
CN1496256A (zh) 2004-05-12
BG108137A (en) 2005-01-31
NO20034056L (no) 2003-11-05
US7312237B2 (en) 2007-12-25
RU2003130377A (ru) 2005-03-10
EE200300440A (et) 2003-12-15
KR20040025904A (ko) 2004-03-26

Similar Documents

Publication Publication Date Title
ATE554756T1 (de) Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
DE69935345D1 (de) Methoden und zusammensetzungen zur prävention und behandlung der anämie
ATE540678T1 (de) Prodrugs aus gaba-analoga, zusammensetzungen und ihre verwendungen
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
ATE407676T1 (de) Topoisomerasehemmern zur behandlung von chirurgischen verklebungen
DE60132777D1 (de) Benzothiazolderivate zur behandlung von alzheimer und parkinson
DE60223694D1 (de) Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
DE60335293D1 (de) Pyrrolopyridazin-verbindungen und verwendungsverfahren dafür zur behandlung von proliferativen erkrankungen
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
EP1651164A4 (de) Zusammensetzung und verfahren zur behandlung von neurologischen erkrankungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE519488T1 (de) Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten
ATE540129T1 (de) Target zur therapie kognitiver behinderungen
DE60108080D1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
DE60027913D1 (de) 5-beta-sapogenin und pseudosapogeninderivate und ihre verwendung zur behandlung von demenz
ATE376444T1 (de) Ibandronsäure zur behandlung und vorbeugung von osteoporose
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE602005019247D1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
DE602006009786D1 (de) Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten
ATE369130T1 (de) Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen
DE60142313D1 (de) Triptolid-analoga zur behandlung von autoimmunkranheiten und entzündungen
DE60139783D1 (de) Gen und pflanzenextrakte, wirksam zur behandlung und prävention von chlamydieninfektionen